Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy

References

• Caugant DA, Brynildsrud OB Neisseria meningitidis: using genomics to understand diversity, evolution and pathogenesis. Nat Rev Microbiol. 2020 Feb;18(2):84–96. doi:10.1038/s41579-019-0282-6. Epub 2019 Nov 8.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease prevention and Control (ECDC). Annual epidemiological report for 2017. Invasive meningococcal disease. Stockholm (Sweden): ECDC; 2019. “https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2017-invasive-meningococcal-disease.pdf” [accessed 2020 Sept 24].
   Google Scholar
• Italian National Health Institute (Istituto Superiore di Sanità, ISS). [Surveillance data on invasive bacterial diseases updated on 23 April 2019]. Italian. http://old.iss.it/binary/mabi/cont/Interim_Report_2018_finale.pdf [accessed 2020 Sept 24].
   Google Scholar
• Piano Nazionale Prevenzione Vaccinale PNPV 2017-2019 [National plan for vaccine prevention NPVP 2017-2019]. Rome (Italy): Ministero della Salute; 2017. Italian. http://www.salute.gov.it/imgs/C_17_pubblicazioni_2571_allegato.pdf
   Google Scholar
• Gandhi A, Balmer P, York LJ. Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®). Postgrad Med. 2016;128(6):548–56. doi:10.1080/00325481.2016.1203238.
   PubMed Web of Science ®Google Scholar
• Trumenba, INN-meningococcal group B vaccine - European medicines agency. https://www.ema.europa.eu/en/documents/product-information/trumenba-epar-product-information_it.pdf [accessed 2020 Sept 24].
   Google Scholar
• Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine. 2012;30(Suppl 2):B87–97. doi:10.1016/j.vaccine.2012.01.033.9.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Giuliani MM, Biolchi A, Pizza M, Beebeejaun K, Lucidarme J, Findlow J, Ramsay ME, Borrow R. Effectiveness of meningococcal B vaccine against endemic hypervirulent Neisseria meningitidis W Strain, England. Emerg Infect Dis. 2016 Feb;22(2):309–11. doi:10.3201/eid2202.150369.
   PubMed Web of Science ®Google Scholar
• Hong E, Giuliani MM, Deghmane AE, Comanducci M, Brunelli B, Dull P, Pizza M, Taha MK. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? Vaccine. 2013 Feb 4;31(7):1113–16. doi:10.1016/j.vaccine.2012.12.022. Epub 2012 Dec 20.
   PubMed Web of Science ®Google Scholar
• Pizza M. 4CMenB, a multicomponent meningococcal vaccine developed for serogroup B meningococci, elicits cross-reactive immunity against serogroups C, W and Y. 15th EMGM congress; 2019 May 27-30; Lisbon, Portugal.
   Google Scholar
• Zhu H, Wang Q, Wen L, Xu J, Shao Z, Chen M, Chen M, Reeves PR, Cao B, Wang L. Development of a multiplex PCR assay for detection and genogrouping of Neisseria meningitidis. J Clin Microbiol. 2012;50(1):46–51. doi:10.1128/JCM.00918-11. PMID: 22090406
   PubMed Web of Science ®Google Scholar
• Fazio C, Neri A, Vacca P, Ciammaruconi A, Arghittu M, Barbui AM, Vocale C, Bernaschi P, Isola P, Galanti IA, et al. Cocirculation of Hajj and non-Hajj strains among serogroup W meningococci in Italy, 2000 to 2016. Euro Surveill. 2019 Jan;24:4. doi:10.2807/1560-7917.ES.2019.24.4.1800183.
   Google Scholar
• Budroni S, Kleinschmidt A, Boucher P, Medini D. Pooled-sera hSBA titres predict individual seroprotection in infants and toddlers vaccinated with 4CMenB. Vaccine. 2016 May 17;34(23):2579–84. doi:10.1016/j.vaccine.2016.04.009.
   PubMed Web of Science ®Google Scholar
• Borrow R, Aaberge IS, Santos GF, Eudey TL, Oster P, Glennie A, Findlow J, Høiby EA, Rosenqvist E, Balmer P, et al. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol. 2005;12:970–76. doi:10.1128/CDLI.12.8.970-976.2005.
   PubMedGoogle Scholar
• Stefanelli P, Neri A, Vacca P, Picicco D, Daprai L, Mainardi G, Rossolini GM, Bartoloni A, Anselmo A, Ciammaruconi A et al. Meningococci of serogroup X clonal complex 181 in refugee camps, Italy. Emerg Infect Dis. 2017 May;23(5):870–72. doi:10.3201/eid2305.161713.
   PubMed Web of Science ®Google Scholar
• Fazio C, Neri A, Renna G, Vacca P, Antonetti R, Barbui AM, Daprai L, Lanzafame P, Rossi L, Santino I, et al. Persistent occurrence of serogroup Y/sequence type (ST)-23 complex invasive meningococcal disease among patients aged five to 14 years, Italy, 2007 to 2013. Euro Surveill. 2015;20:45. doi:10.2807/1560-7917.ES.2015.20.45.30061.
   Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969 Jun 1;129(6):1307–26. doi:10.1084/jem.129.6.1307.
   PubMed Web of Science ®Google Scholar
• Welsch JA, Granoff D. Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody. Clin Vaccine Immunol. 2007 Dec;14(12):1596–602. doi:10.1128/CVI.00341-07. Epub 2007 Oct 3.
   PubMedGoogle Scholar
• Giuliani MM, Biolchi A, Serruto D, Ferlicca F, Vienken K, Oster P, Rappuoli R, Pizza MG, Donnelly J. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine. 2010;28:5023–30.
   PubMed Web of Science ®Google Scholar
• Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch MR, Stella M, Comanducci M, Bambini S, Muzzi A, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. PNAS. 2010 Nov;107(45):19491–95. doi:10.1073/pnas.1013758107.
   Web of Science ®Google Scholar
• Muzzi A, Brozzi A, Serino L, Bodini M, Abad R, Caugant D, Comanducci M, Lemos AP, Gorla MC, Křižová, et al. Genetic meningococcal antigen typing system (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine. 2019 Feb 8;37(7):991–1000. doi:10.1016/j.vaccine.2018.12.061. Epub 2019 Jan 17.
   PubMed Web of Science ®Google Scholar
• Brehony C, Rodrigues CMC, Borrow R, Smith A, Cunney RE, Moxon R, Maiden MCJ. Distribution of bexsero antigen sequence types (BASTs) in invasive meningococcal disease isolates: implications for immunisation. Vaccine. 2016;34:4690–97.
   PubMed Web of Science ®Google Scholar